



March 2007

HELINN **N**NEWS

## HELINN HEALTHCARE AND PIERRE FABRE AQUITAINE: ANOTHER STEP FORWARD IN THEIR BUSINESS RELATIONSHIP

Castres, France, March 1, HELINN HEALTHCARE SA and PIERRE FABRE AQUITAINE announce that they have taken a step forward in their business relationship with the signature of an agreement which foresees the construction of a new manufacturing unit in the Pierre Fabre plant in Pau (France), which gives Helsinn the option to reserve at least 50% of the capacity.



From left:

Riccardo Braglia, CEO, Helsinn  
Healthcare

Alain Sainsot, President, Pierre Fabre  
Aquitaine

Giorgio Calderari, Chief Operations  
Officer, Helsinn Healthcare

Paul Martin, Director Business  
Development Pierre Fabre Aquitaine

Pierre Fabre already manufactures for Helsinn bulk sterile vials of Palonosetron Hydrochloride for the prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) and has started the validation of the manufacturing process in preparation of the launch of the new indication Post-Operative-induced Nausea and Vomiting (PONV).

The new unit will allow Helsinn to better assure the supply chain in injectable drugs for its commercial partners, and will act as complement to its solid oral dosage form plant Helsinn Birex Pharmaceutical, who will manage all the logistic, quality and packaging Operations of the I.V. drugs.



March 2007

# HELINN NEWS

The construction will begin in the month of April and the plant is scheduled to be fully commissioned and the process validated in the first quarter of 2009, so as to allow the commercialization of Palonosteron vials in the summer of the same year.



From right:

Giorgio Calderari,

Alain Sainsot,

Riccardo Braglia,

Pierre Fabre, founder and  
chairman

Paul Martin

Dr. Riccardo Braglia said: "The signing of this agreement is also an occasion for Helsinn to meet Dr. Pierre Fabre and begin a closer business relationship in different other sectors other than manufacturing, wishing to define other potential common business".